Mirvetuximab soravtansine plus Bevacizumab
IMGN853-0421
Phase 3 small_molecule active
Quick answer
Mirvetuximab soravtansine plus Bevacizumab for Ovarian Cancer is a Phase 3 program (small_molecule) at AbbVie with 1 ClinicalTrials.gov record(s).
Program details
- Company
- AbbVie
- Indication
- Ovarian Cancer
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active